



UNITED STATES PATENT AND TRADEMARK OFFICE

dl
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/526,386	02/28/2005	Leonard Mackles	CHAV3.0-032PCT/US	3839
47375	7590	02/05/2007		
OMRI M. BEHR 325 PIERSON AVENUE EDISON, NJ 08837-3123			EXAMINER COTTON, ABIGAIL MANDA	
			ART UNIT	PAPER NUMBER
			1617	
SHORTENED STATUTORY PERIOD OF RESPONSE		MAIL DATE	DELIVERY MODE	
3 MONTHS		02/05/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary	Application No. 10/526,386	Applicant(s) MACKLES, LEONARD	
	Examiner Abigail M. Cotton	Art Unit 1617	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 2/28/05, 10/27/05 and 11/28/06.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 25-43 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 25-43 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Claims 25-43 are pending in the application and are being examined on the merits herein.

Priority

Applicant's claim of priority as a 371 of PCT/US03/28272 filed September 10, 2003, which is a continuation of 10/253,073, filed September 23, 2002, and a continuation of 10/406,869, filed April 4, 2003, which is a continuation-in-part of 10/253,073 filed September 23, 2002, is acknowledged.

Applicant's claim of foreign priority to GERMANY 10146657.9 filed September 21, 2001, is acknowledged.

Specification

The disclosure is objected to because of the following informalities: the phrase "caprylic acid" is spelled incorrectly as "caprilic acid" in the first full paragraph on page 4.

Appropriate correction is required.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claim 28 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claims contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention. In particular, the specification as originally filed does not provide support for the recitation that the glyceride moieties are "selected from the group consisting of caprylic and caproic glycerides," as recited in claim 28. Instead, the specification discloses that the "moieties are selected from the group consisting of capr[y]lic and capric acids," (first full paragraph on page 4), but does not disclose that the moieties can be caproic glycerides, as required by the claim. Appropriate correction is required.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and

Art Unit: 1617

the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 25-43 are rejected under 35 U.S.C. 103(a) as being unpatentable over DE 199 25 289 A1 to Klocker et al, published December 7, 2000, in view of U.S. Patent No. 5,897,858 to Haslwanter et al, issued April 27, 1999, and further in view of JP 07-076526 to Omori et al, published March 20, 1995.

Klocker et al. teaches a pharmaceutical composition for the nasal administration of a water-soluble active agent, comprising the active agent, a neutral oil and optionally a solubility enhancer (see abstract, in particular.) Klocker et al. teaches that the composition is free of water (non-aqueous), and does not require propellants or preservatives (see abstract and column 2, lines 9-15, in particular.) Klocker et al. teaches that the oil can be a triglyceride, such as triglycerides having a fatty acid content that includes caproic and caprylic acid (see paragraph bridging columns 2-3, in particular.) Klocker et al. teaches that the composition can be administered via sprays and/or nose drops (see column 2, lines 20-25, in particular.)

Accordingly, it is considered that Klocker et al. teaches providing a liquid spray for administration of a bioactive material to the nasal cavity having a pharmacologically acceptable non aqueous liquid carrier that is a triglyceride, as in part (a) of claim 25, and a pharmacologically acceptable water soluble bio-active material, as in part (b), the spray being non-aqueous. Regarding the recitation that the bioactive material is soluble

Art Unit: 1617

in the glycol but insoluble in the carrier, the Examiner notes that Klocker et al. teaches the same carrier as that recited, namely a triglyceride, and teaches that the bio-active material is water-soluble, and thus it follows that the bio-active material is insoluble in non-aqueous materials, such as the triglyceride oil, and is soluble in other water-soluble substances, such as the glycol. It is noted that the solubility of compound is a property thereof, and a product and its properties are inseparable. *In re Papesch*, 315 F.2d 381, 137 USPQ 43 (CCPA 1963)

Klocker et al. does not specifically teach that the composition contains an acceptable water soluble glycol, or an ester of a water soluble acid, as recited in claim 25. However, Klocker et al. does teach that the composition can have other components that improve uptake of the drug through the mucous membranes of the nose (see column 5, lines 5-22, in particular.)

Haslwanter et al. teaches a nasal spray having polyethylene glycol (see abstract, in particular.) Haslwanter teaches that water soluble polyethylene polymers can be used to promote moisturization of the nasal spray composition in the nasal cavity (see column 3, lines 55-58, in particular), and teaches that other such moisturization agents include propylene glycol and glycerin (see column 4, lines 24-35, in particular.) Regarding the recitation that the glycol is soluble in the ester of the water soluble acid, it is noted that as Haslwanter et al. teaches the same glycols as that being claimed, it follows that the glycols are also soluble in the claimed ester. It is noted that the

Art Unit: 1617

solubility of compound is a property thereof, and a product and its properties are inseparable. *In re Papesch*, 315 F.2d 381, 137 USPQ 43 (CCPA 1963). Thus, Haslwanter et al. teaches that pharmacologically acceptable water soluble glycols can be provided in nasal spray compositions to moisturize the nasal cavity, and thus teaches providing part (c) of claim 25.

Accordingly, it is considered that one of ordinary skill in the art at the time the invention was made would have found it obvious to provide the water soluble glycol of Haslwanter et al. in the nasal spray composition of Klocker et al, because Klocker et al. teaches a composition that can be applied nasally that and can have other components that improve uptake of the drug through the mucous membranes of the nose, whereas Haslwanter et al. teaches water soluble glycols for nasal sprays that improve moisturization of the nasal cavity, and thus improve administration of the drugs. Thus, it is considered that one of ordinary skill in the art at the time the invention was made would have found it obvious to provide the water soluble glycols of Haslwanter et al. in the nasal spray compositions of Klocker et al, with the expectation of providing an ingredient suitable for improving the administration of the drug by moisturizing the nasal cavity.

Regarding the amount of the water-soluble glycol provided in the composition, as recited in part (c) of claim 25, it is noted that Haslwanter et al. teaches that an amount of polyethylene glycol provided can be 2.5-10% weight/volume, and other moisturizers can

Art Unit: 1617

be provided in an amount of 1-10% by weight (see abstract, in particular), which ranges meet and/or overlap with the recitation that the glycol comprises from 1 to about 5% by weight of the total composition. Furthermore, it is considered that one of ordinary skill in the art at the time the invention was made would have found it obvious to vary and/or optimize the amount of the glycol provided in the composition, according to the guidance provided by Klocker et al. and Haslwanter et al, to provide a composition having desired properties. It is noted that "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955.)

Klocker et al. and Haslwanter et al. do not specifically teach combining a water insoluble ester of a water soluble acid into the composition, as recited in part (b) of claim 25, such as a lactate ester, as in claim 33, including cetyl, lauryl and isostearyl lactate esters, as in claim 35. However, as discussed above, Klocker et al. does teach that the composition can have other components that improve uptake of the drug through the mucous membranes of the nose (see column 5, lines 5-22, in particular.)

Omori et al. teaches a transcutaneous absorption preparation containing lactic acid esters that improve the absorption and penetration of drugs through the skin (see abstract, in particular.) Omori et al. teaches that that lactate esters can be formed with fatty alcohols with carbon numbers of 12-18, include cetyl lactate and lauryl lactate (see

Art Unit: 1617

paragraph 0007, in particular.) Omori et al. teaches that for mucosal skin surfaces in particular, the lactic acid ester penetration enhancer allows easy absorption without excessive stimulation of the mucosal surface (see paragraph 0019, in particular.) Regarding the recitation that the ester is an insoluble ester of a water soluble acid that is soluble in the carrier, it is noted that as Omori et al. teaches the same lactic acid esters as that being claimed, it follows that the esters also have the same solubility characteristics. It is noted that the solubility of compound is a property thereof, and a product and its properties are inseparable. *In re Papesch*, 315 F.2d 381, 137 USPQ 43 (CCPA 1963). Thus, Omori et al. teaches that the esters as in part (b) can be provided to enhance penetration of drugs across mucous membranes.

Accordingly, it is considered that one of ordinary skill in the art at the time the invention was made would have found it obvious to provide the penetration enhancing lactic acid esters of Omori et al. in the nasal spray composition of Klocker et al, because Klocker et al. teaches a composition that can be applied nasally that and can have other components that improve uptake of the drug through the mucous membranes of the nose, whereas Omori et al. teaches that the lactic acid esters enhance penetration of drugs through mucous membranes without excessive stimulation of the membranes. Thus, it is considered that one of ordinary skill in the art at the time the invention was made would have found it obvious to provide the lactic acid esters in the nasal spray compositions of Klocker et al, with the expectation of providing a composition having improved permeation of the drug through the nasal mucous membranes.

The references do not teach the specific steps of dissolving the bioactive material in a glycol, then dissolving in the ester, and dissolving in the carrier, as recited in claim 25. However, as Klocker et al, Haslwanter et al. and Omori et al. teach the desirability of providing the each of the components (a)-(d) in the nasal spray composition, it is considered that one of ordinary skill in the art would have found it obvious to combine vary and/or optimize the steps by which the components are added together, with the expectation of achieving a product suitable for nasal administration. It has been held that merely changing the order of steps in a multi-step process is not a patentable modification absent a showing of unexpected results. *Ex parte Rubin* 128 USPQ 440 (POBA 1959.)

It is furthermore noted that, for the purposes of searching for and applying prior art under 35 U.S.C. 102 and 103, the transitional phrase "consisting essentially of" is being construed as equivalent to "comprising," absent a clear indication in the specification or claims of what is meant by, i.e. what is being excluded from the method and/or composition, by the phrase "consisting essentially of." See, e.g., PPG, 156 F.3d at 1355, 48 USPQ2d at 1355, and MPEP 2111.03.

Regarding claim 26, Klocker et al. teaches that the oil can have medium chain triglycerides (see column 2, lines 65-68, in particular.) Regarding claims 27-28, Klocker et al. teaches that a preferred oil is Miglyol 810, which has capric and caprylic fatty

Art Unit: 1617

acids chains esterified with glycerin or propylene glycol, and also teaches that such oils can be obtained via esterification of such fatty acids as caproic acid (see paragraph bridging column 2 through 3, in particular.) Thus, Klocker et al. teaches the carrier comprising a medium chain length propylene triglyceride, and teaches that the glyceride moieties can be selected from caprylic and caproic glycerides, as recited in the claims.

It is respectfully pointed out that instant claims 29-39 are product-by-process claims. Even though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process. In re Thorpe, 777 F.2d 695, 698, 227 USPQ 964, 966 (Fed Cir. 1985). See MPEP 2113. In the instant case, the combination of references render obvious providing a composition for nasal administration that is non-aqueous and that has the components (a)-(d) as recited in claim 29.

Regarding the specific amount of each component, as in claims 29-30, it is noted that Klocker et al. teaches that the amount of active agent can be from 0.01-15% by weight (see column 4, lines 67-68, in particular), which overlaps with the amount recited in the claim, and exemplifies composition having an active agent (polyhexanide) in a Miglyol 840 oil in a 20% by weight formulation, which would result in about 80% by

Art Unit: 1617

weight of the oil (see Example 4, in particular.) Haslwanter et al. teaches that the glycols can be provided in an amount of 2.5-10% weight/volume (polyethylene glycol) and 1-10% by weight/volume (e.g. propylene glycol (see abstract, in particular.) Omori et al. teaches that the lactic acid ester penetration enhancers can be provided in an amount of 1-30% by weight (see paragraph 0008, in particular.) Furthermore, it is considered that one of ordinary skill in the art at the time the invention was made would have found it obvious to vary and/or optimize the amount of each of the components provided in the composition, according to the guidance provided by Klocker et al, Haslwanter et al. and Omori et al, to provide a composition having desired properties, such as desired nasal administration properties. It is noted that "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955.)

Regarding claims 31-32, Haslwanter et al. teaches providing polyethylene glycol and propylene glycol as moisturizing agents in the compositions, as discussed above. Regarding claims 33-35, Omori et al. teaches providing the alkyl lactates, including lauryl and cetyl lactate, as recited in the claims.

Regarding claim 40, Klocker et al. teaches that the composition can be administered by spraying into the nasal cavity (see column 2, lines 19-25, in particular.) It is furthermore noted that, for the purposes of searching for and applying prior art

Art Unit: 1617

under 35 U.S.C. 102 and 103, the transitional phrase "consisting essentially of" is being construed as equivalent to "comprising," absent a clear indication in the specification or claims of what is meant by, i.e. what is being excluded from the method and/or composition, by the phrase "consisting essentially of." See, e.g., PPG, 156 F.3d at 1355, 48 USPQ2d at 1355, and MPEP 2111.03.

Regarding claims 36-39 and 41-43, Klocker et al. teach that the active agents administered by the composition drugs such as ephedrine and phenylephrine hydrochloride (see column 3, line 45 and 57, in particular), and thus teaches providing the decongestants as recited in the claim, as well as pharmaceutically acceptable salts thereof. It is furthermore noted that Klocker et al. teaches that the active agents are water soluble (see abstract, in particular), as discussed above, and thus it is considered that the drugs are in water-soluble form, as recited in claims 39 and 43.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 25-43 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-2, 4-15, 17-19, 20-23 of copending Application Serial No. 10/406,869 as published in U.S. Patent Application Publication No. 2004/0057907 to Leonard Mackles on March 25, 2004. Although the conflicting claims are not identical, they are not patentably distinct from each other because both the instant and conflicting claims recite compositions containing the same components, and methods of making and methods of use thereof, and differ only in that the instant compositions/methods are "consisting essentially of" the recited components/steps, whereas the conflicting claims recite the compositions "comprising" the components and/or steps. Thus, it is considered that the instant methods and compositions are obvious over the conflicting claims, because one of ordinary skill in the art would have been motivated to provide compositions/methods consisting essentially of, on the basis of the conflicting claims recitation of the necessary ingredients and/or steps. Accordingly, the instant claims 25-43 are not patentably distinct over claims 1-2, 4-15, 17-19, 20-23 of copending Application Serial No. 10/406,869.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Conclusion

No claims are allowed.

The prior art made of record and not relied upon that is considered pertinent to applicant's disclosure is listed in the accompanying PTO-892 form.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Abigail M. Cotton whose telephone number is (571) 272-8779. The examiner can normally be reached on 9:30-6:00, M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1617

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

AMC



SREENI PADMANABHAN
SUPERVISORY PATENT EXAMINER